9-5053743-C-T
Variant names: 
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The NM_004972.4(JAK2):c.615-820C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.242 in 151,312 control chromosomes in the GnomAD database, including 4,746 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
 Genomes: 𝑓 0.24   (  4746   hom.,  cov: 32) 
Consequence
 JAK2
NM_004972.4 intron
NM_004972.4 intron
Scores
 2
Clinical Significance
 Not reported in ClinVar 
Conservation
 PhyloP100:  -0.103  
Publications
10 publications found 
Genes affected
 JAK2  (HGNC:6192):  (Janus kinase 2) This gene encodes a non-receptor tyrosine kinase that plays a central role in cytokine and growth factor signalling. The primary isoform of this protein has an N-terminal FERM domain that is required for erythropoietin receptor association, an SH2 domain that binds STAT transcription factors, a pseudokinase domain and a C-terminal tyrosine kinase domain. Cytokine binding induces autophosphorylation and activation of this kinase. This kinase then recruits and phosphorylates signal transducer and activator of transcription (STAT) proteins. Growth factors like TGF-beta 1 also induce phosphorylation and activation of this kinase and translocation of downstream STAT proteins to the nucleus where they influence gene transcription. Mutations in this gene are associated with numerous inflammatory diseases and malignancies. This gene is a downstream target of the pleiotropic cytokine IL6 that is produced by B cells, T cells, dendritic cells and macrophages to produce an immune response or inflammation. Disregulation of the IL6/JAK2/STAT3 signalling pathways produces increased cellular proliferation and myeloproliferative neoplasms of hematopoietic stem cells. A nonsynonymous mutation in the pseudokinase domain of this gene disrupts the domains inhibitory effect and results in constitutive tyrosine phosphorylation activity and hypersensitivity to cytokine signalling. This gene and the IL6/JAK2/STAT3 signalling pathway is a therapeutic target for the treatment of excessive inflammatory responses to viral infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020] 
 INSL6  (HGNC:6089):  (insulin like 6) The protein encoded by this gene contains a classical signature of the insulin superfamily and is significantly similar to relaxin and relaxin-like factor. This gene is preferentially expressed in testis. Its expression in testis is restricted to interstitial cells surrounding seminiferous tubules, which suggests a role in sperm development and fertilization. [provided by RefSeq, Jul 2008] 
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.94). 
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.293  is higher than 0.05. 
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt | 
|---|---|---|---|---|---|---|---|---|---|---|
| JAK2 | ENST00000381652.4  | c.615-820C>T | intron_variant | Intron 6 of 24 | 1 | NM_004972.4 | ENSP00000371067.4 | |||
| JAK2 | ENST00000636127.1  | c.615-820C>T | intron_variant | Intron 6 of 15 | 5 | ENSP00000489812.1 | 
Frequencies
GnomAD3 genomes   AF:  0.243  AC: 36667AN: 151194Hom.:  4752  Cov.: 32 show subpopulations 
GnomAD3 genomes 
 AF: 
AC: 
36667
AN: 
151194
Hom.: 
Cov.: 
32
Gnomad AFR 
 AF: 
Gnomad AMI 
 AF: 
Gnomad AMR 
 AF: 
Gnomad ASJ 
 AF: 
Gnomad EAS 
 AF: 
Gnomad SAS 
 AF: 
Gnomad FIN 
 AF: 
Gnomad MID 
 AF: 
Gnomad NFE 
 AF: 
Gnomad OTH 
 AF: 
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome   AF:  0.242  AC: 36669AN: 151312Hom.:  4746  Cov.: 32 AF XY:  0.247  AC XY: 18221AN XY: 73854 show subpopulations 
GnomAD4 genome 
 AF: 
AC: 
36669
AN: 
151312
Hom.: 
Cov.: 
32
 AF XY: 
AC XY: 
18221
AN XY: 
73854
show subpopulations 
African (AFR) 
 AF: 
AC: 
6301
AN: 
41280
American (AMR) 
 AF: 
AC: 
4226
AN: 
15092
Ashkenazi Jewish (ASJ) 
 AF: 
AC: 
882
AN: 
3458
East Asian (EAS) 
 AF: 
AC: 
1331
AN: 
5162
South Asian (SAS) 
 AF: 
AC: 
1469
AN: 
4796
European-Finnish (FIN) 
 AF: 
AC: 
3465
AN: 
10482
Middle Eastern (MID) 
 AF: 
AC: 
56
AN: 
294
European-Non Finnish (NFE) 
 AF: 
AC: 
18169
AN: 
67732
Other (OTH) 
 AF: 
AC: 
512
AN: 
2104
 Allele Balance Distribution 
 Red line indicates average allele balance 
 Average allele balance: 0.503 
Heterozygous variant carriers
 0 
 1373 
 2746 
 4120 
 5493 
 6866 
 0.00 
 0.20 
 0.40 
 0.60 
 0.80 
 0.95 
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
 0 
 390 
 780 
 1170 
 1560 
 1950 
 <30 
 30-35 
 35-40 
 40-45 
 45-50 
 50-55 
 55-60 
 60-65 
 65-70 
 70-75 
 75-80 
 >80 
Age
Alfa 
 AF: 
Hom.: 
Bravo 
 AF: 
Asia WGS 
 AF: 
AC: 
919
AN: 
3478
ClinVar
Not reported inComputational scores
Source: 
Name
Calibrated prediction
Score
Prediction
 BayesDel_noAF 
 Benign 
 DANN 
 Benign 
 PhyloP100 
Splicing
Name
Calibrated prediction
Score
Prediction
 SpliceAI score (max) 
Details are displayed if max score is > 0.2
 Find out detailed SpliceAI scores and Pangolin per-transcript scores at 
Publications
 You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.